AstraZeneca plc’s (AZN) “Overweight” Rating Reaffirmed at Barclays PLC

Barclays PLC restated their overweight rating on shares of AstraZeneca plc (LON:AZN) in a research note issued to investors on Thursday, May 11th. They currently have a GBX 6,000 ($75.90) price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on the stock. Shore Capital reiterated a sell rating on shares of AstraZeneca plc in a research note on Wednesday, May 10th. HSBC Holdings plc reiterated a reduce rating and set a GBX 4,200 ($53.13) price objective on shares of AstraZeneca plc in a research note on Friday, May 5th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($49.34) price objective on shares of AstraZeneca plc and gave the stock a sell rating in a research note on Wednesday, May 3rd. J P Morgan Chase & Co restated a neutral rating and issued a GBX 4,500 ($56.93) price target (up previously from GBX 4,200 ($53.13)) on shares of AstraZeneca plc in a research note on Sunday, April 30th. Finally, Sanford C. Bernstein set a GBX 4,736 ($59.91) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Friday, April 28th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of GBX 5,121.80 ($64.79).

Shares of AstraZeneca plc (LON AZN) opened at 5284.00 on Thursday. The firm’s market cap is GBX 66.90 billion. The stock’s 50 day moving average price is GBX 5,087.18 and its 200-day moving average price is GBX 4,684.86. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.

WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/06/17/astrazeneca-plcs-azn-overweight-rating-reiterated-at-barclays-plc-updated-updated-updated.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

What are top analysts saying about AstraZeneca plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit